Kairos Pharma Ltd (KAPA)

$1.22 -0.05 (-3.94%)
Market Cap 26.35M
Revenue (ttm) 0.00
Net Income (ttm) -2.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 456,161
Avg Vol 1,240,680
Day's Range N/A - N/A
Shares Out 20.74M
Stochastic %K 70%
Beta N/A
Analysts Strong Sell
Price Target $8.33

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology
Sector: Healthcare
Phone: 310-948-2356
Address:
2355 Westwood Boulevard, Suite 139, Los Angeles, United States
Wintermelonjuice
Wintermelonjuice Oct. 7 at 10:21 AM
$KAPA strange, co has a presentation at ESMO but has yet to announce.
1 · Reply
PandaSamurais
PandaSamurais Oct. 7 at 1:38 AM
Everyone will be watching ticker PRHI tmr!!🚨 PRHI is one of those tickers that has the recipe to see a massive rally. Had a very strong close after hours with a close like that, I wont be surprised if this heads to $4+ tmr. Don't miss out PRHI bulls!!🚨 $KAPA $IMG $BNAI $GIPR
0 · Reply
stockforce123
stockforce123 Oct. 7 at 12:45 AM
$KAPA Kairos Pharma - "Our technologies target a high value, large market - a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market" https://investors.kairospharma.com/why-invest/default.aspx
0 · Reply
stockforce123
stockforce123 Oct. 7 at 12:32 AM
$KAPA The Global Anti-androgens Market is projected to grow from 5.78 USD Billion in 2024 to 12.3 USD Billion by 2035, reflecting a robust growth trajectory. ENV105 is for the win. The market is expected to expand at a compound annual growth rate (CAGR) of 7.13% from 2025 to 2035. By 2035, the market valuation is anticipated to reach 12.3 USD Billion, indicating substantial growth opportunities. In 2024, the market is valued at 5.78 USD Billion, laying a strong foundation for future expansion. Growing adoption of antiandrogens due to increasing awareness of hormonal disorders is a major market driver. https://www.marketresearchfuture.com/reports/antiandrogens-market-12199
0 · Reply
Nouja
Nouja Oct. 6 at 9:14 PM
$KAPA still a good day!
0 · Reply
TB85
TB85 Oct. 6 at 6:55 PM
$KAPA Still wonder, why the lack of attention for this gem!?💎 A phase-3 company, should not be valued this low. Where are the big buyers? They dont believe in Kairos, or what!??
1 · Reply
stockforce123
stockforce123 Oct. 6 at 5:39 PM
$KAPA "We're proving that sometimes the biggest innovations come from the smallest teams."
0 · Reply
stockforce123
stockforce123 Oct. 6 at 5:25 PM
$KAPA Worth listening again about getting funding at kairos time. CEO's words on meaning of Kairos and timing for funding at 5:40 mark: "Kairos is a great term for the opportune moment or right time and it had a lot of meaning for me that our Therapeutics really are designed to intervene at the right time when patients become resistant to a drug. It also really envelops what has happened with our company. We were always able to get funding at the right time in the nick of time. We're all able to get our trial started just in time, and so timing really has a lot to do with our company, and also it has a spiritual meaning of God's time. I really believe that has been a force behind". youtube.com/watch?v=W5ytLxx...
0 · Reply
Shane_Drinion
Shane_Drinion Oct. 6 at 5:15 PM
$KAPA I sure would like to know what a legit oncology ace such as @telomerase thinks of Kairos.
2 · Reply
TB85
TB85 Oct. 6 at 5:02 PM
$KAPA I can't help be a little worried that a sudden offering might happen. To run Phase 3, they will either need a partner, or raise capital themselves. What do you guys think, what is most likely?? No bashing here, just a question. You'd rather not be caught with an offering, if it can be avoided.
2 · Reply
Latest News on KAPA
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 18, 2025, 8:00 AM EDT - 18 days ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 11, 2025, 8:00 AM EDT - 25 days ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 3, 2025, 8:15 AM EDT - 4 weeks ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 4 weeks ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 28, 2025, 12:28 PM EDT - 2 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 16, 2025, 8:30 AM EDT - 2 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 2:08 PM EDT - 2 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jul 15, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Jun 3, 2025, 8:15 AM EDT - 4 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 24, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 31, 2025, 7:00 AM EDT - 6 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Mar 20, 2025, 7:30 AM EDT - 7 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 26, 2025, 7:00 AM EST - 7 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 18, 2025, 8:30 AM EST - 8 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 11, 2025, 8:30 AM EST - 8 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Feb 6, 2025, 8:30 AM EST - 8 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 28, 2025, 8:15 AM EST - 8 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 21, 2025, 8:30 AM EST - 9 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Jan 7, 2025, 8:15 AM EST - 9 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 26, 2024, 7:51 AM EST - 10 months ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 16, 2024, 12:15 PM EST - 10 months ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Dec 3, 2024, 8:30 AM EST - 10 months ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 26, 2024, 8:30 AM EST - 11 months ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Kairos Pharma Prices $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Feb 14, 2024, 6:16 PM EST - 1 year ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma Files For U.S. IPO

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

Wintermelonjuice
Wintermelonjuice Oct. 7 at 10:21 AM
$KAPA strange, co has a presentation at ESMO but has yet to announce.
1 · Reply
PandaSamurais
PandaSamurais Oct. 7 at 1:38 AM
Everyone will be watching ticker PRHI tmr!!🚨 PRHI is one of those tickers that has the recipe to see a massive rally. Had a very strong close after hours with a close like that, I wont be surprised if this heads to $4+ tmr. Don't miss out PRHI bulls!!🚨 $KAPA $IMG $BNAI $GIPR
0 · Reply
stockforce123
stockforce123 Oct. 7 at 12:45 AM
$KAPA Kairos Pharma - "Our technologies target a high value, large market - a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market" https://investors.kairospharma.com/why-invest/default.aspx
0 · Reply
stockforce123
stockforce123 Oct. 7 at 12:32 AM
$KAPA The Global Anti-androgens Market is projected to grow from 5.78 USD Billion in 2024 to 12.3 USD Billion by 2035, reflecting a robust growth trajectory. ENV105 is for the win. The market is expected to expand at a compound annual growth rate (CAGR) of 7.13% from 2025 to 2035. By 2035, the market valuation is anticipated to reach 12.3 USD Billion, indicating substantial growth opportunities. In 2024, the market is valued at 5.78 USD Billion, laying a strong foundation for future expansion. Growing adoption of antiandrogens due to increasing awareness of hormonal disorders is a major market driver. https://www.marketresearchfuture.com/reports/antiandrogens-market-12199
0 · Reply
Nouja
Nouja Oct. 6 at 9:14 PM
$KAPA still a good day!
0 · Reply
TB85
TB85 Oct. 6 at 6:55 PM
$KAPA Still wonder, why the lack of attention for this gem!?💎 A phase-3 company, should not be valued this low. Where are the big buyers? They dont believe in Kairos, or what!??
1 · Reply
stockforce123
stockforce123 Oct. 6 at 5:39 PM
$KAPA "We're proving that sometimes the biggest innovations come from the smallest teams."
0 · Reply
stockforce123
stockforce123 Oct. 6 at 5:25 PM
$KAPA Worth listening again about getting funding at kairos time. CEO's words on meaning of Kairos and timing for funding at 5:40 mark: "Kairos is a great term for the opportune moment or right time and it had a lot of meaning for me that our Therapeutics really are designed to intervene at the right time when patients become resistant to a drug. It also really envelops what has happened with our company. We were always able to get funding at the right time in the nick of time. We're all able to get our trial started just in time, and so timing really has a lot to do with our company, and also it has a spiritual meaning of God's time. I really believe that has been a force behind". youtube.com/watch?v=W5ytLxx...
0 · Reply
Shane_Drinion
Shane_Drinion Oct. 6 at 5:15 PM
$KAPA I sure would like to know what a legit oncology ace such as @telomerase thinks of Kairos.
2 · Reply
TB85
TB85 Oct. 6 at 5:02 PM
$KAPA I can't help be a little worried that a sudden offering might happen. To run Phase 3, they will either need a partner, or raise capital themselves. What do you guys think, what is most likely?? No bashing here, just a question. You'd rather not be caught with an offering, if it can be avoided.
2 · Reply
LuckyBoy_PL
LuckyBoy_PL Oct. 6 at 2:03 PM
$KAPA
0 · Reply
ChrisBAB
ChrisBAB Oct. 6 at 1:55 PM
$KAPA
0 · Reply
Warrent_jr
Warrent_jr Oct. 6 at 7:00 AM
$KAPA +$12 Tagrisso made $6.9B in 2024, but resistance remains. Kairos Pharma’s ENV105 shows early promise to overcome this, helping patients and saving billions. Big pharma interest, including AstraZeneca, highlights its potential. With trials progressing, KAPA’s future is bright—$12 isn’t a dream, it’s a real possibility!
0 · Reply
stockforce123
stockforce123 Oct. 6 at 5:49 AM
$KAPA
0 · Reply
stockforce123
stockforce123 Oct. 6 at 4:33 AM
$KAPA The most important fact is that both 2018-2020 and the 2023-2025 phase 2 prostate cancer trials of ENV105 with the same class of anti-androgen drugs (3 different drugs from J&J and Pfizer) all showed remarkable efficacy results, with the most recent one reported on 9/18 with a median 18 months of progression-free survival, far surpassing the expected 4-6 months of PFS. In the principle investigator, Dr. Edwin Posadas’s own words, both P2 trials showed “class effect of desensitization, and I think that we’re seeing an experience in this population (the current phase 2 trial) which looks very promising.” J&J and Pfizer are taking serious notes on these comments and the results. This is not a coincidence, this is class effect of the combination therapy of ENV105 with three top drugs in the market. Partnerships are coming.
0 · Reply
LuckyBoy_PL
LuckyBoy_PL Oct. 6 at 4:00 AM
$KAPA
0 · Reply
stockforce123
stockforce123 Oct. 5 at 2:31 AM
$KAPA The Non-Small Cell Lung Cancer (NSCLC) market is valued at ~USD 30B in 2024 and is poised for strong growth through 2034 to ~ $65B. TAGRISSO is AstraZeneca's leading drug for EGFR-mutant NSCLC. Kairos Pharma's ENV105 is being tested with Tagrisso (osimertinib) in P1 lung cancer trial and the initial results will be announced this year. https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=akpr The CEO said "ENV105 restores tumor sensitivity to Tagrisso (osimertinib) by targeting CD105 and blocking the resistance signaling cascade. Tagrisso alone brought in $5.8 billion in revenue in 2023, yet it lacks a targeted solution once resistance develops. If ENV105 can extend the clinical benefit of such drugs by even a few months, that could represent significant added value for both companies and extension of cancer-free life for patients. While Kairos is focused on developing our drugs through the clinical trial pipeline, we are always open to exploring partnership models as they arise." https://invezz.com/news/2025/08/15/interview-kairos-pharma-ceo-john-yu-on-env105s-potential-partnerships-for-growth/
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 4 at 5:53 PM
$KAPA $EPIX $HALO $STAK Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
stockforce123
stockforce123 Oct. 4 at 4:52 AM
$KAPA Talk about AstraZeneca's TAGRISSO (osimertinib) for lung cancer! $6.9B sale in 2024!! Still, it fails when resistance kicks in. Kairo Pharma's ENV105 is saving billions of dollars of research and potential sales for AstraZeneca. The P1 lung cancer trial's initial data will be released this year. This will further confirm its safety and efficacy. AstraZeneca is bidding againist J&J for partnership with Kairos Pharma. https://www.prnewswire.com/news-releases/tagrisso-sets-the-stage-for-market-leadership-in-oncology-with-strong-growth-prospects--delveinsight-302397863.html
1 · Reply
Wintermelonjuice
Wintermelonjuice Oct. 4 at 4:30 AM
$KAPA PT?
0 · Reply
stockforce123
stockforce123 Oct. 4 at 3:30 AM
$KAPA Cedars-Sinai Medical Center, the sponsor of Kairos Pharma's P1 and P2 trials is consistently recoginized 10 years in a row as one of the best hospitals in the United States. https://youtu.be/t1EuMznFCLI?si=QQZGAeL2F90wtCPl
0 · Reply
Warrent_jr
Warrent_jr Oct. 3 at 11:47 PM
$KAPA KAPA may be small now, but the carotuximab results at ESMO 2025 prove it’s not size that matters, it’s data. Safe + early efficacy in NSCLC & prostate combo studies put them on Big Pharma’s radar. Analysts see targets $4–$12 (avg $8.33) from here. Science first, 🚀 follows.!!!let's Gooooooo!
0 · Reply